MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.66
-0.15
-1.17%
Closed 16:41 09/22 EDT
OPEN
12.81
PREV CLOSE
12.81
HIGH
13.02
LOW
12.21
VOLUME
1.24M
TURNOVER
--
52 WEEK HIGH
27.82
52 WEEK LOW
9.74
MARKET CAP
1.28B
P/E (TTM)
-6.0901
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Morgan Stanley 18th Annual Global
Business Wire · 09/08 10:30
Why Is Epizyme (EPZM) Up 0.6% Since Last Earnings Report?
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/03 15:31
Is Epizyme (NASDAQ:EPZM) A Risky Investment?
Simply Wall St. · 08/18 18:05
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Zacks · 08/05 15:29
Morgan Stanley Maintains Overweight on Epizyme, Lowers Price Target to $29
Morgan Stanley maintains Epizyme (NASDAQ:EPZM) with a Overweight and lowers the price target from $31 to $29.
Benzinga · 08/05 14:14
Epizyme shares are trading lower after the company reported worse-than-expected Q2 sales results.
Benzinga · 08/04 17:31
Epizyme EPS misses by $0.01, misses on revenue
Epizyme (NASDAQ:EPZM): Q2 GAAP EPS of -$0.58 misses by $0.01. Revenue of $2.47M (-58.1% Y/Y) misses by $1.99M. Press Release
seekingalpha · 08/04 15:31
Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates
Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 11:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EPZM. Analyze the recent business situations of Epizyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EPZM stock price target is 28.38 with a high estimate of 36.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 228
Institutional Holdings: 101.77M
% Owned: 100.29%
Shares Outstanding: 101.48M
TypeInstitutionsShares
Increased
68
9.08M
New
59
-6.71M
Decreased
34
1.49M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.48%
Pharmaceuticals & Medical Research
+0.12%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Robert Bazemore
Chief Financial Officer
Paolo Tombesi
Chief Scientific Officer
Jeffery Kutok
Other
Shefali Agarwal
Other
Matthew Ros
Director
Michael Giordano
Director
Pablo Legorreta
Independent Director
Andrew Allen
Independent Director
Kenneth Bate
Independent Director
Grant Bogle
Independent Director
Kevin Conroy
Independent Director
Carl Goldfischer
Independent Director
Richard Pops
Independent Director
Victoria Richon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EPZM
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Epizyme Inc stock information, including NASDAQ:EPZM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPZM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPZM stock methods without spending real money on the virtual paper trading platform.